Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts (NCT05625659)
Comparison of Breast Cancer Screening With Dual-Energy Contrast-Enhanced Spectral Mammography to Digital Breast Tomosynthesis in Women With Dense Breasts (Contrast Mammography Imaging Screening Trial
🩺 Plain-English Summary (8th-Grade Level)
The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Aim 1: To evaluate the performance of CESM compared to DBT at baseline for breast-cancer screening in women with dense breasts. Aim 2: To evaluate the performance of CESM compared to DBT at the 1-year follow up for breast-cancer screening in women with dense breasts.
Who can join: Review the eligibility criteria below.
Location: University of Alabama, Birmingham — Birmingham, Alabama
Age range: 45 Years to 74 Years
🧪 Interventions in This Study
- Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of Alabama, Birmingham — Birmingham, Alabama
- Boca Raton Regional Hospital - Christine E. Lynn Women's Health and Wellness Institute — Boca Raton, Florida
- Lake Medical Imaging — The Villages, Florida
- Massachusetts General Hospital — Boston, Massachusetts
- Boston Breast Diagnostic Center — Wellesley Hills, Massachusetts
- Henry Ford Health — Detroit, Michigan
- Thomas Jefferson University — Sewell, New Jersey
- Memorial Sloan Kettering Cancer Center — New York, New York
- Carolina Breast Imaging Specialists — Greenville, North Carolina
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- University of Virginia — Charlottesville, Virginia
- St. Joseph's Hospital — London, Ontario
📞 Contact the Study Coordinator
Phone: (212) 746-6000
Email: chc4050@med.cornell.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.